GSK, Genmab amend licensing deal over cancer drug
GlaxoSmithKline and Genmab have revised their licensing deal for Arzerra, their drug candidate for blood cancers.
In this move Genmab will get $134.4 million in upfront payments but will see its future milestones and funding commitments reduced.
The amended agreement, which will have "a material impact on Genmab's 2010 financial guidance," calls for GSK to develop the drug for autoimmune diseases while both companies continue developing the treatment for cancer indications.
Source: ReutersÂ
